First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)

Document Type

Presentation

Publication Date

4-18-2023

Keywords

oregon; chiles

Abstract

AACR Annual Meeting; 2023 April 18; Orlando, FL

Clinical Institute

Cancer

Specialty

Oncology

This document is currently not available here.


Share

COinS